MediciNova's MN-166 advances as neuroprotective option for MS
This article was originally published in Scrip
Executive Summary
With the help of a grant from the US National Institutes of Health (NIH), the US venture MediciNova is taking one of its main development projects, MN-166 (ibudilast), into a US Phase IIb trial for progressive multiple sclerosis (MS).